← Back to Search

Behavioural Intervention

Text Message Reminders for Breast Cancer Medication Adherence

N/A
Waitlist Available
Led By Margaret Barton-Burke, PhD, RN
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance) >/= 18 years of age
Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is testing whether text reminders can help people remember to take their cancer medication.

Who is the study for?
This trial is for adults with breast cancer who are starting palbociclib treatment and own a smartphone. They must be able to use the OhMD app, speak English, and manage their own healthcare without relying on caregivers.Check my eligibility
What is being tested?
The study tests if text message reminders via the OhMD app can help patients remember to take their medication palbociclib as scheduled, compared to using a paper drug diary.See study design
What are the potential side effects?
Since this trial focuses on the method of reminding rather than the medication itself, there are no direct side effects from the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older and starting treatment with Ibrance for breast cancer.
Select...
I am starting Ibrance for the first time, alone or with Femara or Faslodex.
Select...
I can send and receive texts using the study app.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Accuracy rate of medication self-administration

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of Care + InterventionExperimental Treatment1 Intervention
Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
Group II: Standard of CareActive Control1 Intervention
Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,928 Previous Clinical Trials
591,763 Total Patients Enrolled
202 Trials studying Breast Cancer
95,124 Patients Enrolled for Breast Cancer
Margaret Barton-Burke, PhD, RNPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

Palbociclib (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04216576 — N/A
Breast Cancer Research Study Groups: Standard of Care, Standard of Care + Intervention
Breast Cancer Clinical Trial 2023: Palbociclib Highlights & Side Effects. Trial Name: NCT04216576 — N/A
Palbociclib (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04216576 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what regions can participants access this research trial?

"As of now, there are 7 clinical trial sites open for recruitment. These include Memorial Sloan Kettering Nassau (Limited Protocol Activities) in Rockville Centre, Memorial Sloan Kettering Commack (Limited Protocol Activities) in Commack, and Memorial Sloan Kettering Monmouth (Limited Protocol Activities) in Middletown. There is also a selection of other medical centres accepting patients."

Answered by AI

How many participants are engaged in this clinical investigation?

"Absolutely. According to the information provided on clinicaltrials.gov, this research program was first advertised in December of 2019 and has since been updated in July 2022. Currently, 100 participants are sought from seven distinct medical centres."

Answered by AI

Is the patient enrollment for this experiment still open?

"As evidenced by clinicaltrials.gov, this trial is still seeking participants; it was initially published on December 27th 2019 and last revised on July 28th 2022."

Answered by AI
~6 spots leftby Dec 2024